FMP

FMP

Enter

EDIT - Editas Medicine, Inc...

Financial Summary of Editas Medicine, Inc.(EDIT), Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative

photo-url-https://financialmodelingprep.com/image-stock/EDIT.png

Editas Medicine, Inc.

EDIT

NASDAQ

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

5 USD

-0.3 (-6%)

About

ceo

Dr. Gilmore O'Neill M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In additio...

CIK

0001650664

ISIN

US28106W1036

CUSIP

28106W103

Address

11 Hurley Street

Phone

617 401 9000

Country

US

Employee

265

IPO Date

Feb 3, 2016

Summary

CIK

0001650664

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

28106W103

ISIN

US28106W1036

Country

US

Price

5

Beta

2

Volume Avg.

2.12M

Market Cap

411.19M

Shares

-

52-Week

4.45-11.69

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.42

P/B

-

Website

https://www.editasmedicine.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest EDIT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep